405 related articles for article (PubMed ID: 28374784)
1. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
[TBL] [Abstract][Full Text] [Related]
2. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
3. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.
Avan A; Maftouh M; Funel N; Ghayour-Mobarhan M; Boggi U; Peters GJ; Giovannetti E
Curr Med Chem; 2014; 21(8):975-89. PubMed ID: 23992325
[TBL] [Abstract][Full Text] [Related]
4. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
5. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
6. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
7. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
8. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
9. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
10. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
11. Biomarker development in MET-targeted therapy.
Zhang Y; Du Z; Zhang M
Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
[TBL] [Abstract][Full Text] [Related]
12. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
Hack SP; Bruey JM; Koeppen H
Oncotarget; 2014 May; 5(10):2866-80. PubMed ID: 24930887
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
14. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
15. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
16. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
17. C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview.
Rashed WM
Crit Rev Oncol Hematol; 2018 Nov; 131():7-15. PubMed ID: 30293708
[TBL] [Abstract][Full Text] [Related]
18. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
19. MET receptor in oncology: From biomarker to therapeutic target.
Malik R; Mambetsariev I; Fricke J; Chawla N; Nam A; Pharaon R; Salgia R
Adv Cancer Res; 2020; 147():259-301. PubMed ID: 32593403
[TBL] [Abstract][Full Text] [Related]
20. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]